A promising new treatment for patients with pulmonary arterial hypertension
In September, the Food and Drug Administration (FDA) announced priority review of sotatercept, Merck’s activin signaling inhibitor for the treatment of adults with pulmonary […]
A promising new treatment for patients with pulmonary arterial hypertension Read More »